MedTrace Logo

Safety and Feasibility of the Injectable BL-1040 Implant

NCT00557531 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-02-03

No results posted yet for this study

Summary

This is a Phase I, multi-center, open label study designed to assess the safety and feasibility of the injectable BL-1040 implant to provide scaffolding to infarcted myocardial tissue.

Conditions

Interventions

DEVICE

BL-1040

2 mL of BL-1040

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • BioLineRx, Ltd.

    lead INDUSTRY

Principal Investigators

  • Paul Vermeersch, MD · Antwerp MC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-01-31
Completion
2014-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557531 on ClinicalTrials.gov